AstraZeneca reports Fasenra approved in China for severe eosinophilic asthma

AstraZeneca’s Fasenra has been approved in China by the country’s National Medical Products Association, or NMPA, for the maintenance treatment of patients 12 years of age and older with severe eosinophilic asthma, or SEA. Ruud Dobber, Executive Vice President, BioPharmaceuticals Business Unit, AstraZeneca said: “Today’s approval is an important step forward in the treatment of severe asthma in China, which affects millions of patients. Those living with severe asthma will soon have access to Fasenra, which rapidly targets eosinophils, resulting in a significant reduction of asthma exacerbations and clinically meaningful symptom relief for patients.”